Filtered By:
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 3663 results found since Jan 2013.

High-on-Aspirin Platelet Reactivity Differs Between Recurrent Ischemic Stroke Associated With Extracranial and Intracranial Atherosclerosis
CONCLUSIONS: Recurrent stroke due to ECAS was more strongly associated with HAPR and insufficient antiplatelet inhibition than was that due to ICAS. Artery-to-artery embolism was associated with HAPR in recurrent ischemic stroke as a result of ICAS or ECAS.PMID:35796267 | PMC:PMC9262451 | DOI:10.3988/jcn.2022.18.4.421
Source: Journal of Clinical Neurology - July 7, 2022 Category: Neurology Authors: Kyung Chul Noh Hye-Yeon Choi Ho Geol Woo Jun Young Chang Sung Hyuk Heo Dae-Il Chang Bum Joon Kim Source Type: research

Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies
AbstractPurpose of ReviewThe benefit of using antiplatelet monotherapy in acute ischemic stroke and secondary stroke prevention is well established. In the last few years, several large randomized trials showed that the use of short-term dual antiplatelet therapy in particular stroke subtypes may reduce the risk of recurrent ischemic events. The aim of this article is to provide a critical analysis of the current evidence and recommendations for the use of antiplatelet agents for stroke prevention.Recent FindingsLong-term therapy with aspirin, clopidogrel, or aspirin plus extended-release dipyridamole is recommended for se...
Source: Current Neurology and Neuroscience Reports - October 13, 2022 Category: Neuroscience Source Type: research

Predictors of In-Hospital Mortality after Acute Ischemic Stroke (P01.227)
CONCLUSIONS: After AIS, patients with severe stroke and post stroke complications were 5 and 22.2 times more likely to die while ASA and other antiplatelet agent use before AIS were associated respectively with 1.6 and 1.5 times greater chances of survival after AIS. Unlike previous reports from smaller studies, LLA were not predictive of in-patient mortality.Disclosure: Dr. Moonis has nothing to disclose. Dr. Tuggatari has nothing to disclose. Dr. Izzy has nothing to disclose. Dr. Sundar has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Moonis, M., Tuggatari, A., Izzy, S., Sundar, B. Tags: P01 Cerebrovascular Disease I Source Type: research

Thoracoscopic Pulmonary Vein Isolation and Atrial Appendage Ligation (TPVIAL) versus Medical Management in Atrial Fibrillation Patients with Prior Stroke (P1.126)
CONCLUSIONS: TPVIAL may become an important therapeutic tool for reducing recurrent stroke in AF patients.Disclosure: Dr. Waters has nothing to disclose. Dr. Hedna has nothing to disclose. Dr. Khanna has nothing to disclose. Dr. Miles has nothing to disclose. Dr. Price has nothing to disclose. Dr. Schmalfuss has nothing to disclose. Dr. Robertson has nothing to disclose. Dr. Karimi has nothing to disclose. Dr. Beaver has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Waters, M., Hedna, V., Khanna, A., Miles, W., Price, C., Schmalfuss, I., Robertson, D., Karimi, A., Beaver, T. Tags: Cerebrovascular Disease and Interventional Neurology: Atrial Fibrillation and Miscellaneous Source Type: research

Abstract 263: The Risk of Stroke or Systemic Embolism for Antithrombotic Treatment Episodes among Non-Valvular Atrial Fibrillation (NVAF) Patients Session Title: Poster Session II
Conclusion: Warfarin TTR ≥55% was associated with the greatest reduction in stroke/SE among the antithrombotic treatment groups examine here. Future studies should examine modifiable factors to improve outcomes for patients with warfarin TTR <55% or those who are off antithrombotic therapy.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: An, J., Niu, F., Lang, D. T., Le, P. T., Jazdzewski, K. P., Rashid, N., Mendes, R., Dills, D., Meissner, B., Bruno, A. Tags: Session Title: Poster Session II Source Type: research

Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.
CONCLUSIONS: Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy. This could be a novel strategy for cardioembolic stroke prevention potentially by affecting cardiac remodelling, in contrast to secondary anticoagulant therapy. PMID: 25798683 [PubMed - as supplied by publisher]
Source: Neurological Research - March 24, 2015 Category: Neurology Tags: Neurol Res Source Type: research

Effect of oral cilostazol on acute neurological deterioration and outcome of noncardioembolic minor stroke
Conclusion In noncardioembolic stroke, combined antithrombotic therapy with early oral cilostazol in the acute phase appears to be associated with a good outcome in patients with progressive stroke.
Source: Journal of Clinical Gerontology and Geriatrics - December 18, 2015 Category: Geriatrics Source Type: research

Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor
AbstractApproximately 1 in 3 –4 patients presenting with an ischemic stroke will also have atrial fibrillation (AF), and AF-related strokes can be effectively prevented using oral anticoagulant therapy (OAC), either with well-controlled vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs). In a ddition, OAC use (both VKAs and NOACs) is associated with a 26% reduction in all-cause mortality (VKAs) or an additional 10% mortality reduction with NOACs relative to VKAs. The decision to use OAC in individual AF patient is based on the estimated balance of the benefit from ischemic stroke reducti...
Source: Advances in Therapy - December 7, 2016 Category: Drugs & Pharmacology Source Type: research

Antiplatelet therapy after stroke: should it differ in the acute and chronic phase after stroke
Purpose of review Reviewing existing evidence regarding well tolerated and effective antiplatelet treatment in patients with acute or chronic, noncardioembolic ischemic stroke and transient ischemic attack (TIA). Recent findings For patients with high-risk stroke or TIA, for instance, minor stroke or high-risk TIA, or stroke of atherosclerotic origin with evidence suggesting risk of artery-to-artery embolism or with high-grade, symptomatic arterial stenosis, early initiated, short-term dual antiplatelet (e.g. aspirin and clopidogrel) is effective in reducing the risk of recurrent stroke and other vascular events which...
Source: Current Opinion in Neurology - December 20, 2017 Category: Neurology Tags: CEREBROVASCULAR DISEASE: Edited by Hugh S. Markus Source Type: research

Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania
ConclusionsThe 90-day mortality of stroke presenting at MNH is 50%, much higher than in higher income settings. Although severe stroke presentations are a major factor, efforts to improve the quality of care and prevent complications of stroke are urgently needed. Acute stroke interventions with low number needed to treat represent challenging long-term goals.
Source: International Journal for Quality in Health Care - August 28, 2018 Category: International Medicine & Public Health Source Type: research

Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients
AbstractAntiplatelet agents may increase the risk of infections via suppressing platelet-mediated immune response. Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission. A retrospective cohort study was conducted of acute ischemic stroke patients who were admitted to our hospital from 2015 to 2018. Included patients received uninterrupted clopidogrel or aspirin therapy and did not take other antiplatelet agents throughout their stay. The interest outcome was development of pneumonia after stroke. Conditional logistic regression model after ...
Source: Journal of Thrombosis and Thrombolysis - October 9, 2020 Category: Hematology Source Type: research

A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro
Conclusion: Atorvastatin, alone and in combination with aspirin can promote anti-inflammatory effect by modulating the secretome profile of Mo and MSCs. Our results suggest that stroke trials involving the use of intravenous MSCs should consider the effect of aspirin and atorvastatin, both of which are administered to the majority of hospitalized ischemic stroke patients.
Source: Frontiers in Pharmacology - April 20, 2021 Category: Drugs & Pharmacology Source Type: research

Comparison of aspirin and P2Y12 inhibitors for secondary prevention of ischaemic stroke: A systematic review and meta-analysis
CONCLUSION: This meta-analysis suggests that P2Y12 inhibitors are more effective than aspirin in preventing recurrent ischaemic stroke among ischaemic stroke patients despite the absence of any effect on a new ischaemic or haemorrhagic stroke, a new clinical vascular event, all-cause death, and major or minor bleeding events.PMID:35619249 | DOI:10.2174/2772432817666220526162144
Source: Pharmacological Reviews - May 27, 2022 Category: Drugs & Pharmacology Authors: Kaili Zhang Yongle Wang Tingting Liu Xiaoyuan Niu Source Type: research